MannKind Corporation (MNKD) Receiving Somewhat Positive Media Coverage, Study Shows

News stories about MannKind Corporation (NASDAQ:MNKD) have trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. MannKind Corporation earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 44.7552361383853 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:

MannKind Corporation (MNKD) opened at 3.37 on Friday. The company has a market capitalization of $352.78 million, a price-to-earnings ratio of 2.54 and a beta of 3.16. The firm has a 50-day moving average price of $3.26 and a 200-day moving average price of $1.82. MannKind Corporation has a 52 week low of $0.67 and a 52 week high of $6.96.

MannKind Corporation (NASDAQ:MNKD) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.10). The business had revenue of $2.16 million for the quarter, compared to the consensus estimate of $2.75 million. MannKind Corporation had a net margin of 71.60% and a negative return on equity of 24.93%. During the same period in the prior year, the business earned $0.08 earnings per share. Analysts anticipate that MannKind Corporation will post ($0.91) EPS for the current fiscal year.

A number of analysts recently issued reports on the company. Zacks Investment Research upgraded MannKind Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, October 11th. HC Wainwright assumed coverage on MannKind Corporation in a research note on Tuesday, October 10th. They set a “buy” rating on the stock. ValuEngine lowered MannKind Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, October 18th. Finally, Maxim Group reiterated a “buy” rating on shares of MannKind Corporation in a research note on Friday, September 1st. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the stock. MannKind Corporation presently has a consensus rating of “Hold” and a consensus price target of $0.92.

TRADEMARK VIOLATION WARNING: “MannKind Corporation (MNKD) Receiving Somewhat Positive Media Coverage, Study Shows” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at

In other MannKind Corporation news, Director Kent Kresa purchased 166,600 shares of the firm’s stock in a transaction on Friday, October 13th. The shares were acquired at an average cost of $6.00 per share, with a total value of $999,600.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.40% of the stock is owned by company insiders.

MannKind Corporation Company Profile

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control.

Insider Buying and Selling by Quarter for MannKind Corporation (NASDAQ:MNKD)

Receive News & Ratings for MannKind Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MannKind Corporation and related companies with's FREE daily email newsletter.

Leave a Reply